Protocol Ledger

NCT04090736 · Phase III · ACTIVE NOT RECRUITING

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

Interventional Phase III clinical trial protocol NCT04090736 sponsored by PETHEMA Foundation in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-09-24 Enrollment: 302 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04090736
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)302 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04090736
Protocol FieldVerified Registry Value
NCT IdentifierNCT04090736
Consolidated Lead SponsorPETHEMA Foundation
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment302 participants (ACTUAL)
Registered Start Date2019-09-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04090736
Hospital Research SiteLocationSite Profile
Hospital Universitario Virgen de la VictoriaMálaga, SpainOpen Hospital Dossier ->
Hospital Universitario Central de AsturiasOviedo, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI